Connect with us

Medical Devices

Three popular home devices used in Covid-19 treatment

Published

on


Three popular home <a class=devices used in Covid-19 treatment, Newsline”>

Cape Town – Medical devices are finding their way into people’s homes and are increasingly becoming popular because of the coronavirus.

For better control of the spread of Covid-19, contact-tracing and warning apps have been implemented.

In South Africa, the government has also turned to technology with its Bluetooth contact tracing app, COVID Alert SA, aimed at slowing the spread of the virus.

The app uses Bluetooth contact-tracing technology to let people know if they have been in contact with someone who has Covid-19.

Here are some of the medical devices being used at home to treat Covid-19:

Pulse Oximeter

Despite a new study showing that the pulse oximeter are more error-prone in people with darker skin, these devices are becoming increasingly popular for home use, with pharmacies in KwaZulu-Natal reportedly running short of the oxygen monitors.

The device works by measuring the percentage of oxygen in the blood when clipped on to a fingertip. Doctors say it is mostly beneficial to people who don’t need immediate hospital attention but are at high risk of developing serious symptoms from Covid-19, like those with underlying health conditions.

The South African Medical Association (Sama) has also urged the public to only buy the device if they really need it, as they are an important tool for doctors to monitor patients who have Covid-19 symptoms.

Nebuliser machine

The nebuliser can be used to relieve symptoms of various lung conditions by administering both quick-relief medicines and long-term control medicines. It helps to deliver medication directly to the lungs and the respiratory system where it is needed and relieves symptoms such as breathlessness and tightness in the chest.

Nebulisers work by converting a solution into a fine spray, which makes it easier to inhale the drugs. A nebuliser is a machine, which creates a mist of medicine that is breathed in through a mouthpiece.

Face mask ventilator

Often used for chronic lung conditions, some doctors use them for people with Covid-19. A face mask ventilator is a non-invasive method of supporting a person’s breathing and oxygen levels. To use one, a person wears a mask that fits over the nose and mouth while air blows into their airways and lungs.

People with Covid-19 may use a face mask ventilator if they are having difficulty breathing or do not have sufficient oxygen levels.

Source: https://newsline.co.za/2021/01/12/three-popular-home-devices-used-in-covid-19-treatment/

Medical Devices

Medical Foam Market Size to Reach $38.1 Billion by 2027 | CAGR: 6.1%: AMR

Increase in number of aged population and requirement for enhanced comfort for patients and rise in need for protective packaging of medical devices and medical wearables fuel the growth of the global medical foam market. Moreover, based on region, the market across Asia-Pacific held lion’s share in 2019 and is expected to lead the trail throughout the forecast period.

Published

on

January 14, 2021 09:30 ET | Source: Allied Market Research

Portland, OR, Jan. 14, 2021 (GLOBE NEWSWIRE) — According to the report published by Allied Market Research, the global medical foam industry estimated at $23.6 billion in 2019, and is projected to reach $38.1 billion by 2027, growing at a CAGR of 6.1% from 2020 to 2027. The report offers an in-depth analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and changing market trends.

Increase in number of aged population and requirement for enhanced comfort for patients and rise in need for protective packaging of medical devices and medical wearables fuel the growth of the global medical foam market. On the other hand, side-effects such as retention of heat, heaviness, and time to adjust sleeping position of mattresses restrain the market growth to a certain extent. Nevertheless, rise in number of private and government hospitals across the globe is anticipated to provide an array of opportunities for the market players in the approaching time.

Request PDF Brochure: https://www.alliedmarketresearch.com/request-sample/8450

Covid-19 scenario:

  • The number of patients admitted to hospitals has increased during Coivd-19, which positively impacted the sales of medical foam.
  • Patients infected with Covid-19 require a long time for recovery, thereby increasing the number of beds, which further surged the demand for the medical foam.
  • Growing demand for PPE kits has further contributed to the growth of the market.

The medical foam market is segmented on the basis of type, material, application and region. Based on type, the flexible segment dominated the market with the largest share in 2019, contributing to nearly half of the global market. Furthermore, the segment is also expected to grow at the highest CAGR of 6.7% from 2020 to 2027. Moreover, the report also analyzes segments including rigid and molded.

Based on application, the market is divided on the basis of packaging, bedding and cushioning, device and components, and others. The bedding and cushioning segment held the largest share in 2019, with more than half of the global market. However, the device and components segment is estimated to portray the highest CAGR of 7.8% during the forecast period.

Get Detailed COVID-19 Impact Analysis on the Medical Foam Market: https://www.alliedmarketresearch.com/request-for-customization/8450?reqfor=covid

Based on region, the market is analyzed across various regions including Asia-Pacific, Europe, North America, and LAMEA. The Asia-Pacific region accounted for the highest market share with nearly half of the total revenue in 2019, and would lead the trail throughout the forecast period. In addition, the region is also anticipated to register the fastest CAGR of 6.6% during the forecast period.

Major market players in the report include Apollo Foam Limited, Advanced Medical Solutions Group plc, Draka Interfoam B.V., Foamtec Medical, UFP Technologies, Freudenberg Performance Materials s.a.s, Technical Foam Services Limited, General Plastics Manufacturing Company, and Transcontinental Advanced Coating.

Interested in Procuring This Report? Visit Here: https://www.alliedmarketresearch.com/medical-foam-market/purchase-options

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter

Get more information: https://www.alliedmarketresearch.com/library-access

About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.

Contact:David Correa5933 NE Win Sivers Drive#205, Portland, OR 97220United StatesToll Free: 1-800-792-5285UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1-855-550-5975help@alliedmarketresearch.comWeb: https://www.alliedmarketresearch.comFollow Us on: LinkedIn Twitter

Contact:David Correa5933 NE Win Sivers Drive#205, Portland, OR 97220United StatesToll Free: 1-800-792-5285UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1-855-550-5975help@alliedmarketresearch.comWeb: https://www.alliedmarketresearch.comFollow Us on: LinkedIn Twitter

AMR Logo.png

AMR Logo.png

LOGO URL | Copy the link below

AMR Logo.png

Formats available:

The medical foam market is segmented on the basis of type, material, application and region. Based on type, the flexible segment dominated the market with the largest share in 2019, contributing to nearly half of the global market. Furthermore, the segment is also expected to grow at the highest CAGR of 6.7% from 2020 to 2027. Moreover, the report also analyzes segments including rigid and molded.

Source: https://www.globenewswire.com/news-release/2021/01/14/2158775/0/en/Medical-Foam-Market-Size-to-Reach-38-1-Billion-by-2027-CAGR-6-1-AMR.html

Continue Reading

Medical Devices

FDA issues action plan for regulating AI in medical devices

MedTech industry news

Published

on


UpperEdge

Dive Brief:

  • FDA on Tuesday released an action plan for establishing a regulatory approach to the fast-developing field of artificial intelligence and machine learning-based Software as a Medical Device (SaMD).
  • The action plan comes in response to substantial stakeholder feedback, including hundreds of public comments, on an April 2019 discussion paper that proposed a framework for regulating modifications to AI and SaMD.
  • FDA’s latest publication on the subject is the next step on a path to draft guidance for a “predetermined change control plan” that would include the types of modifications covered and the methodology used to implement the changes in a way that manages risks to patients, the agency said.

Dive Insight:

The action plan comes amid calls for regulatory clarity from AdvaMed and others on machine learning algorithms that continually evolve without the need for manual updates. FDA so far has approved or cleared only devices that use “locked” algorithms that do not change in this way.

GE Healthcare, Medtronic and Philips are among those working toward incorporating AI capabilities in their treatments and investing in the tech. Medtronic, for example, is focused on AI-aided technologies that would support robotics, navigation, imaging and pre-operative planning for spine surgery. The medtech giant in November acquired French spinal surgery company Medicrea, gaining access to an AI database of more than 5,000 surgical cases.

And last month, Philips announced a $2.8 billion deal to buy Bio Telemetry, which specializes in remote cardiac diagnostics and monitoring, including wearable heart monitors and AI-based data analytics.

Since the release of FDA’s discussion paper nearly two years ago, industry has been waiting for an update on its oversight plan. Given that FDA has proposed a total product lifecycle approach to AI/machine learning that could allow improvements to devices after they are in use, finalized guidance or regulations would help developers better understand requirements and potential liabilities, a GAO/National Academy report said in November.

In the new action plan document, FDA touted the ability to learn from real-world experience to improve device performance as one of the greatest benefits of AI/ML in software. It suggested a “predetermined change control plan” could enable evaluation and monitoring of software from premarket development through postmarket performance.

The approach has attracted strong interest since it was described in the 2019 discussion paper, FDA said. The agency noted that Caption Health, which received marketing authorization in February for the first cardiac ultrasound software with AI to guide users, used a predetermined change control plan.

“This framework would enable FDA to provide a reasonable assurance of safety and effectiveness while embracing the iterative improvement power of artificial intelligence and machine learning-based software as a medical device,” the regulator said.

FDA said it will issue draft guidance on this concept in response to stakeholder suggestions. The draft will propose what should be included in SaMD pre-specifications and the algorithm change protocol to support the safety and effectiveness of AI/ML SaMD algorithms.

The agency also addressed stakeholder concerns about algorithmic bias, saying it will support regulatory science to develop methodology to evaluate and improve machine learning algorithms. Such methodology would target identification and elimination of bias, and evaluation and promotion of algorithm robustness.

“Healthcare delivery is known to vary by factors such as race, ethnicity, and socio-economic status; therefore, it is possible that biases present in our health care system may be inadvertently introduced into the algorithms,” the agency said. FDA “recognizes the crucial importance for medical devices to be well suited for a racially and ethnically diverse intended patient population and the need for improved methodologies for the identification and improvement of machine learning algorithms,” the action plan stated.

FDA pledged to encourage harmonization of good machine learning practices and to hold a public workshop on labeling to support transparency regarding AI/ML-based devices.

The agency also said it will work with stakeholders on a voluntary basis to pilot collection and monitoring of real-world performance data, to support the total product lifecycle approach to oversight of AI/ML-based SaMD.

Source: https://www.medtechdive.com/news/fda-issues-action-plan-for-regulating-ai-in-medical-devices/593280/

Continue Reading

Trending